Neurocognitive disorder is a term that describes decreased mental function due to a medical disease other than psychiatric illness. Various neurocognitive disorders, such as mild cognitive impairment, delirium, and dementia, are characterized by a decline in the level of cognitive functioning. Neurocognitive deficit is impairment/reduction in cognitive functions and impact nerve cells and often affects an individual’s ability to remember, reason, and make decisions. Moreover, such disorders have different clinical characteristics with Lewy body disease, front temporal degeneration, traumatic brain injury, cerebrovascular disease, Alzheimer disease, and infections showing the common causes. Of which, Alzheimer’s is the most common cause of neurocognitive disorder. In the early stages of Alzheimer’s, individuals are unable to remember recent events, names of people, and conversations and may experience depression. People with neurocognitive disorders experience side effects, such as anxiety, depression, apathy, and sleep disturbance (hypersomnia and insomnia).
Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/2676
Neurocognitive disorder treatments include bed rest, physical therapy, pain medications, and surgery. Moreover, antibiotics can be used to clear the remaining infections, which may affect the brain, such as meningitis.
High prevalence of neurocognitive disorder around the world is expected to propel growth of the global neurocognitive disorder treatment market over the forecast period. Moreover, rise in cardiovascular issues, adoption of unhealthy work practices, and advancement in technology and inventions such as Artificial Intelligence (AI) is also expected to drive the market growth.
Furthermore, increasing prevalence of respiratory diseases, increase in addiction of drugs and alcohol in youth, growing geriatric population, and changing climate conditions are some major factors expected to augment the growth of the global neurocognitive disorder treatment market.
With the increasing prevalence of neurocognitive disorders around the world, the demand for neurocognitive disorder treatment is also increasing. For instance, in April 2019, Kyowa Hakko Kirin Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application (NDA) for istradefylline (KW-6002), for use as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD). Moreover, in May 2019, FDA approved Neuronascent’s investigational new drug application for NNI-362, its therapy candidate for Alzheimer’s disease, allowing it to move ahead with a Phase 1 clinical trial, the company announced.
By Disorder Type:
- Alzheimer Disease
- Parkinson’s Disease
- Huntington’s Disease
By Drug Class:
- Cholinesterase Inhibitors
- N-methyl-D Aspartate Receptors Antagonists
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
North America is expected to witness significant growth in the global neurocognitive disorder treatment market due to the high prevalence of neurocognitive disorder, increasing adoption of advance precautious methods, satisfactory reimbursement policies, rise in penetration of life science analytics for monitoring health changes continuously, and rise in adoption of advanced technology in the region. For instance, as per the World Health Organization (WHO), over 35.6 million people around the world are living with dementia. Moreover, the number of geriatric population and related dementia patients is expected to reach around 65.7 million by 2030 and around 115.4 million by 2050. Furthermore, according WHO, the prevalence of dementia in the North America is increasing rapidly with age and gender, doubling every 5.5 years.
Major players active in the global neurocognitive disorder treatment market are Problodrug AG, Purdue Pharma, T3D Therapeutics, Roche, Proclar Biosciences, Mediti Pharma Inc., Immunobrain, Eisai, Biogen, A C immune, Abbive, A B Science, and Ono Pharmaceuticals.
In May 2019, T3D therapeutics received US$ 9 million grant from the National Institute of Aging (NIA) to develop drug T3D-959 for neurocognitive disease.
In March 2018, Biogen Inc. acquired Pfizer Inc.’s PF-04958242, a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia (CIAS).
Direct Purchase This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2676
Reasons to Buy this Neurocognitive Disorder Treatment Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Neurocognitive Disorder Treatment Market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Neurocognitive Disorder Treatment Market
➡Leading company profiles reveal details of key Neurocognitive Disorder Treatment Market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Neurocognitive Disorder Treatment Market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Neurocognitive Disorder Treatment Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Neurocognitive Disorder Treatment Industry Impact
Chapter 2 Global Neurocognitive Disorder Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Neurocognitive Disorder Treatment (Volume and Value) by Type
2.3 Global Neurocognitive Disorder Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Neurocognitive Disorder Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Neurocognitive Disorder Treatment Market Analysis
Chapter 6 East Asia Neurocognitive Disorder Treatment Market Analysis
Chapter 7 Europe Neurocognitive Disorder Treatment Market Analysis
Chapter 8 South Asia Neurocognitive Disorder Treatment Market Analysis
Chapter 9 Southeast Asia Neurocognitive Disorder Treatment Market Analysis
Chapter 10 Middle East Neurocognitive Disorder Treatment Market Analysis
Chapter 11 Africa Neurocognitive Disorder Treatment Market Analysis
Chapter 12 Oceania Neurocognitive Disorder Treatment Market Analysis
Chapter 13 South America Neurocognitive Disorder Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Neurocognitive Disorder Treatment Business
Chapter 15 Global Neurocognitive Disorder Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Request Here For PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2676
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027